

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	MERGER
EFFECTIVE DATE:	01/29/2010

CONVEYING PARTY DATA

Name	Execution Date
Xenomix, Inc.	01/25/2010

RECEIVING PARTY DATA

Name:	Trovagene, Inc.
Street Address:	11055 Flintkote Avenue
City:	San Diego
State/Country:	CALIFORNIA
Postal Code:	92121

PROPERTY NUMBERS Total: 2

Property Type	Number
Application Number:	11137935
Application Number:	11351799

CORRESPONDENCE DATA

Fax Number: (617)542-2241
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Email: ddubiel@mintz.com
 Correspondent Name: Matthew Pavao
 Address Line 1: Mintz Levin
 Address Line 2: One Financial Center
 Address Line 4: Boston, MASSACHUSETTS 02111

ATTORNEY DOCKET NUMBER:	29480-503CIP&29480-502UTI
NAME OF SUBMITTER:	Matthew Pavao

Total Attachments: 4
 source=MergerDoc#page1.tif

OP \$80.00 11137935

501256755

**PATENT
 REEL: 024809 FRAME: 0079**

source=MergerDoc#page2.tif
source=MergerDoc#page3.tif
source=MergerDoc#page4.tif

ARTICLES OF MERGER
(Profit Corporations)

The following articles of merger are submitted in accordance with the Florida Business Corporation Act, pursuant to section 607.1105, Florida Statutes.

First: The name and jurisdiction of the **surviving** corporation:

<u>Name</u>	<u>Jurisdiction</u>	<u>Document Number</u> (if known/ applicable)
TrovaGene, Inc.	Delaware	

Second: The name and jurisdiction of each **merging** corporation:

<u>Name</u>	<u>Jurisdiction</u>	<u>Document Number</u> (if known/ applicable)
Xenomics, Inc.	Florida	P02000047789

Third: The Plan of Merger is attached.

Fourth: The merger shall become effective on the date the Articles of Merger are filed with the Florida Department of State.

OR / / (Enter a specific date. NOTE: An effective date cannot be prior to the date of filing or more than 90 days after merger file date.)

Fifth: Adoption of Merger by **surviving** corporation - (COMPLETE ONLY ONE STATEMENT)
The Plan of Merger was adopted by the shareholders of the surviving corporation on _____.

The Plan of Merger was adopted by the board of directors of the surviving corporation on
January 5, 2010 and shareholder approval was not required.



Sixth: Adoption of Merger by **merging** corporation(s) (COMPLETE ONLY ONE STATEMENT)
The Plan of Merger was adopted by the shareholders of the merging corporation(s) on December 18, 2009.

The Plan of Merger was adopted by the board of directors of the merging corporation(s) on
_____ and shareholder approval was not required.

(Attach additional sheets if necessary)

SAH
1-27-2010

Seventh: **SIGNATURES FOR EACH CORPORATION**

<u>Name of Corporation</u>	<u>Signature of an Officer or Director</u>	<u>Typed or Printed Name of Individual & Title</u>
TrovaGene, Inc.		Bruce Huebner, CEO
Xenomics Inc.		Bruce Huebner, CEO
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____

1-27-2010

**ARTICLES OF MERGER
OF
XENOMICS, INC., a Florida Corporation
INTO
TROVAGENE, INC., a Delaware Corporation**

The undersigned corporations organized and existing under and by virtue of the General Corporation Law of the State of Delaware and the General Corporation Act of the State of Florida, **DO HEREBY CERTIFY:**

FIRST: That the name and state of incorporation of each of the constituent corporations of the merger are as follows:

<u>NAME</u>	<u>STATE OF INCORPORATION</u>
Xenomics, Inc.	Florida
TrovaGene, Inc.	Delaware

SECOND: An Amended and Restated Agreement and Plan of Merger has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations pursuant to Title 8, Section 252, subsection (c) of the General Corporation Law of the State of Delaware and Section 607.1101 of the Florida Business Corporation Act.

THIRD: The surviving corporation is TrovaGene, Inc., a Delaware corporation, and its name shall be TrovaGene, Inc.

FOURTH: The address of the registered office of TrovaGene, Inc. in the State of Delaware, its state of incorporation, is 160 Greentree Drive, Suite 101, Dover, Delaware and its registered agent at such address is National Registered Agents, Inc. TrovaGene, Inc., the surviving corporation is deemed to have appointed the Secretary of State of Florida as its agent for service of process in a proceeding to enforce any obligation or the rights of dissenting shareholders of Xenomics, Inc.. Trovagen, Inc. agrees to promptly pay to the dissenting shareholders of Xenomics, Inc., if any, the amount to which they are entitled under Section 607.1302 of the Florida Business Corporation Act.

FIFTH: The Certificate of Incorporation of the surviving corporation shall be its Certificate of Incorporation.

SIXTH: The Amended and Restated Agreement and Plan of Merger is on file at office of the surviving corporation at 11055 Flintkote Avenue, San Diego, California 92121.

SEVENTH: A copy of the Amended and Restated Agreement and Plan of Merger will be furnished by the surviving corporation on request, without cost, to any stockholder of the constituent corporations.

EIGHTH: The authorized capital stock of Xenomics, Inc. was 120,000,000 shares, of which 100,000,000 were designated as Common Stock with a par value of \$0.0001 per share, and 20,000,000 of which were designated as Preferred Stock with a par value of \$0.001 per share. Of the 20,000,000 shares of Preferred Stock, \$0.001 par value, 277,100 have been designated as Series A Convertible Preferred Stock.

NINTH: The effective date of the Agreement and Plan of Merger shall be the date of filing this Certificate of Merger with the Secretary of State of Delaware and the Department of State of Florida.

IN WITNESS WHEREOF, the undersigned have executed this Certificate this 25th day of January 2010.

XENOMICS, INC., a Florida corporation

By: /s/ Bruce Huebner
Name: Bruce Huebner
Title: Chief Executive Officer

TROVAGENE, INC., a Delaware corporation

By: /s/ Bruce Huebner
Name: Bruce Huebner
Title: Chief Executive Officer